• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    8/4/23 5:32:24 PM ET
    $ACGN
    $AHG
    $BDRX
    $CNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Real Estate
    Get the next $ACGN alert in real time by email

    Gainers

    • Akso Health Group (NASDAQ:AHG) stock increased by 10.7% to $0.34 during Friday's after-market session. Akso Health Group's trading volume hit 54.8K shares by close, accounting for 167.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $7.7 million.
    • T2 Biosystems (NASDAQ:TTOO) shares rose 10.08% to $0.27. T2 Biosystems's trading volume hit 35.7 million shares by close, accounting for 51.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $79.2 million.
    • MSP Recovery (NASDAQ:LIFW) shares rose 9.5% to $0.16. The company's market cap stands at $54.5 million.
    • Context Therapeutics (NASDAQ:CNTX) shares increased by 7.47% to $1.15. The market value of their outstanding shares is at $18.3 million.
    • Soligenix (NASDAQ:SNGX) shares moved upwards by 7.0% to $0.6. The company's market cap stands at $4.9 million.
    • Sonendo (NYSE:SONX) stock increased by 6.72% to $1.27. The market value of their outstanding shares is at $65.1 million.

    Losers

    • Tivic Health Systems (NASDAQ:TIVC) shares declined by 38.4% to $0.04 during Friday's after-market session. Today's trading volume for this security ended up closing at 63.9 million shares, which is 480.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $5.0 million.
    • Aceragen (NASDAQ:ACGN) shares declined by 20.93% to $0.59. The company's market cap stands at $4.9 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) shares declined by 10.16% to $5.75. The company's market cap stands at $1.3 million.
    • Trxade Health (NASDAQ:MEDS) stock declined by 8.41% to $9.15. The market value of their outstanding shares is at $6.2 million.
    • iBio (AMEX:IBIO) shares decreased by 7.88% to $0.62. Trading volume for this security closed at 272.1K, accounting for 61.1% of its average full-day volume over the last 100 days. The company's market cap stands at $10.4 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock fell 7.57% to $0.72. At the close, TC BioPharm (Holdings)'s trading volume reached 71.4K shares. This is 11.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACGN
    $AHG
    $BDRX
    $CNTX

    CompanyDatePrice TargetRatingAnalyst
    iBio Inc.
    $IBIO
    10/21/2025$5.00Outperform
    Oppenheimer
    iBio Inc.
    $IBIO
    10/17/2025$2.00Outperform
    Leerink Partners
    Context Therapeutics Inc.
    $CNTX
    9/18/2025$5.00Buy
    Guggenheim
    Context Therapeutics Inc.
    $CNTX
    4/21/2025Outperform
    William Blair
    Context Therapeutics Inc.
    $CNTX
    1/8/2025$4.00Mkt Outperform
    JMP Securities
    Context Therapeutics Inc.
    $CNTX
    11/25/2024$9.00Buy
    D. Boral Capital
    iBio Inc.
    $IBIO
    5/28/2024$5.00Buy
    Chardan Capital Markets
    Context Therapeutics Inc.
    $CNTX
    5/16/2024$4.50Overweight
    Piper Sandler
    More analyst ratings

    $ACGN
    $AHG
    $BDRX
    $CNTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, CEO AND PRESIDENT Schaber Christopher J bought $20,000 worth of shares (15,132 units at $1.32), increasing direct ownership by 3,993% to 15,511 units (SEC Form 4)

    4 - SOLIGENIX, INC. (0000812796) (Issuer)

    10/3/25 1:18:09 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Lehr Martin A. bought $70,080 worth of shares (100,000 units at $0.70) (SEC Form 4)

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/10/25 5:26:21 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer, Corp. Sec Levit Alex C. bought $11,520 worth of shares (20,000 units at $0.58), increasing direct ownership by 222% to 29,000 units (SEC Form 4)

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    6/10/25 5:23:47 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AHG
    $BDRX
    $CNTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

    PRINCETON, N.J., March 26, 2026 /PRNewswire/ --Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to dusquetide (the active pharmaceutical ingredient in SGX945) for the treatment of Behçet's Disease, following review of the recently published Phase 2a clinical results demonstrating biological efficacy and safety in patients with Be

    3/26/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Reports Full Year 2025 Operating and Financial Results

    Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. "We believe 2025 was a year of significant progr

    3/23/26 4:16:40 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AHG
    $BDRX
    $CNTX
    SEC Filings

    View All

    SEC Form 20-F filed by Biodexa Pharmaceuticals plc American Depositary Shs

    20-F - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/27/26 5:09:45 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

    6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/27/26 5:00:06 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tivic Health Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/25/26 4:25:57 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ACGN
    $AHG
    $BDRX
    $CNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on iBio with a new price target

    Oppenheimer initiated coverage of iBio with a rating of Outperform and set a new price target of $5.00

    10/21/25 7:20:34 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on iBio with a new price target

    Leerink Partners initiated coverage of iBio with a rating of Outperform and set a new price target of $2.00

    10/17/25 8:34:58 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Context Therapeutics with a new price target

    Guggenheim initiated coverage of Context Therapeutics with a rating of Buy and set a new price target of $5.00

    9/18/25 8:39:06 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AHG
    $BDRX
    $CNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Banjak Marc

    4 - iBio, Inc. (0001420720) (Issuer)

    3/27/26 4:05:18 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Liu Wenjuan

    3 - Akso Health Group (0001702318) (Issuer)

    3/27/26 6:46:26 AM ET
    $AHG
    Real Estate

    SEC Form 4 filed by Duran Felipe

    4 - iBio, Inc. (0001420720) (Issuer)

    3/23/26 7:31:15 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AHG
    $BDRX
    $CNTX
    Leadership Updates

    Live Leadership Updates

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

    Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product' strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma's recently announced €38 million Series C financing Saint-Genis-Pouilly, France, 28 October 2025 – Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Karen L. Smith, MD, PhD, MBA, LLM a

    10/28/25 8:00:00 AM ET
    $CNTX
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AHG
    $BDRX
    $CNTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by iBio Inc.

    SC 13G - iBio, Inc. (0001420720) (Subject)

    11/14/24 8:47:49 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AHG
    $BDRX
    $CNTX
    Financials

    Live finance-specific insights

    View All

    Context Therapeutics Reports Full Year 2025 Operating and Financial Results

    Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. "We believe 2025 was a year of significant progr

    3/23/26 4:16:40 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

    SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio's strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and will include a presentation from Martin Brenner, DVM, Ph.D., iBio's Chief Executive Officer and Chief Scientific Officer, and Cory Schwartz, Ph.D., the Company's Director of Research and Early Development. iBio is engineering a selective bispecific antibo

    3/16/26 4:30:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell

    11/6/25 9:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care